%0 Journal Article
%T Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial
%A Catherine Lemiere
%A Frank Albers
%A Hector Ortega
%A Jean-Pierre Llanos
%A Mark Forshag
%A Robert Price
%A Steven Yancey
%J Archive of "Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology".
%D 2019
%R 10.1186/s13223-019-0348-z
%X a Mean ACQ-5 scores, b geometric mean blood eosinophil counts including proportions of subjects with mean ACQ-5 score£¿¡Ư£¿1.5/<£¿1.5 and blood eosinophil counts£¿¡Ư£¿150/<£¿150 cells/¦̀L. Mean ACQ-5 scores and geometric blood eosinophil counts were measured during the open label period and following treatment discontinuation. Error bars represent 95% confidence interval. Reference line for a at a mean ACQ-5 score of 1.5. Reference line for b at a geometric mean blood eosinophil count of 150 cells/¦̀L. ACQ-5 Asthma Control Questionnaire-5, SC subcutaneou
%K Severe eosinophilic asthma
%K Cessation of treatment
%K Asthma control
%K Blood eosinophils
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558891/